Weight-Loss Drugs Show Promise Against Sleep Apnea, Review Finds

Obstructive sleep apnea (OSA), a disorder in which the airway narrows or blocks during sleep, disrupts a full night's rest for about one in eight people worldwide. Researchers have now reviewed how GLP-1 receptor agonists — a class of weight-loss and diabetes drugs — affect the condition, since obesity is a major contributing factor. The review, published in JAMA Otolaryngology–Head Neck Surgery, combined data from four medical databases covering studies from January 2016 to November 2025.

Across six meta-analyses, the drugs cut breathing interruptions by 5.7 to 21.9 events per hour. In major Phase III trials, tirzepatide reduced interruptions by 50% to 63%, about 20 to 24 fewer events per hour, and between 42% and 50% of patients achieved complete remission of the disorder after one year, compared with 14% to 16% on placebo. Much of the effect comes from weight loss, which reduces fat around the neck, throat and tongue, leaving more room for air to flow.

Tirzepatide became the first FDA-approved medication for moderate to severe sleep apnea in adults with obesity in December 2024. Researchers said early lab and animal studies suggest additional mechanisms may be involved, such as reduced sensitivity in the carotid body and restored leptin signaling, which could help keep throat muscles firm during sleep.

The gold-standard treatment, continuous positive airway pressure (CPAP), still cuts more events overall — about 31 per hour compared with about 22 for tirzepatide — but only 30% to 60% of patients stick with CPAP consistently. Weight regained after stopping the medication could limit its long-term benefit, and the drugs mainly help patients whose apnea is linked to obesity rather than airway structure.